Punjab, Haryana FDA to curb black-marketing against COVID-19 drugs

CHANDIGARH: The Food and Drugs Administration (FDA) Haryana and Punjab government are taking preventive measures to put an end to black marketing and sale of Covid-19 drugs like Remdesivir and Actemra in Delhi from these states.

The drugs are administered to the patients having severe coronavirus sympstoms and are sold in the national capital at higher prices after being purchased in Gurugram. For the purpose of checking black marketinging, both states will now procure these drugs directly from authorized wholesalers only for tertiary care facilities at Covid hospitals.
Narendra Ahooja, state drug controller of FDA Haryana said that, “Out of 4984 active patients, 81 patients are on oxygen and 11 are on ventilators. With these details, a fair assessment can be made for procurement to avoid black marketing.”

Data have been prepared by the State drug authorities for medicines required as per patients admitted in the ICUs and on ventilators to keep a check on hoarding. 100 Remdesivir and 200 Actemra have been procured from CIPLA and have been stocked at a warehouse in Rohtak, according to sources.

  • Related Posts

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Laser rescued an Imperiled Food Pipe in Sir Ganga Ram Hospital

    An Impacted Denture accidently  had lodged inside it New Delhi: In a remarkable medical achievement, doctors at Sir Ganga Ram Hospital successfully removed an impacted dental plate that had accidentally…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing